To the Editor:Chimeric antigen receptor(CAR)-T cells targeting CD19 have transformed the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia(R/R B-ALL)therapy.[1]However,cytokine release syndrome(C...To the Editor:Chimeric antigen receptor(CAR)-T cells targeting CD19 have transformed the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia(R/R B-ALL)therapy.[1]However,cytokine release syndrome(CRS)represents a serious and potentially life-threatening complication,marked by excessive proinflammatory cytokine release,poses a severe,potentially fatal complication,manifesting as fever,nausea,fatigue,and,in severe cases,multi-organ failure.展开更多
基金This work was supported by grants from the National Natural Science Foundation of China(Nos.82330005,82400212,and 82200144)the open fund of Hubei Key Laboratory of Biological Targeted Therapy Research(No.202302).
文摘To the Editor:Chimeric antigen receptor(CAR)-T cells targeting CD19 have transformed the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia(R/R B-ALL)therapy.[1]However,cytokine release syndrome(CRS)represents a serious and potentially life-threatening complication,marked by excessive proinflammatory cytokine release,poses a severe,potentially fatal complication,manifesting as fever,nausea,fatigue,and,in severe cases,multi-organ failure.
